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Abstract: Leukemia is the number one cancer affecting children in the nation, with acute
lymphoblastic leukemia being the most prevalent classification.1 While new and innovative
treatment protocols have greatly increased the success rate of primary cancer patients, those who
face relapse receive a much more dismal prognosis. Recent studies have shown that patients who
relapse quite frequently have developed drug-resistant clones of the original cancer cells, leading
to a need for various secondary treatment options. The drug-resistance is due to clonal mutations
that take place within the cancer cell, most often because of an outside pressure or stress within
the environment of the cell. In fact, studies show that in many cases the chemotherapy and
radiation treatment administered to the leukemia patients provides the added pressures necessary
to promote these clonal mutations, leading to treatment-resistant cells and the onset of relapsed
leukemia. Various immunotherapies are becoming the front-line secondary treatment option due
to their high success rates and innovative techniques. Monoclonal antibodies such as
Blinatumomab or Inatuzumab are currently the primary targets of research for acute
lymphoblastic leukemia secondary therapy. However, dual therapy treatments of cancers have
shown increased rates of event-free survival, overall survival, and progression-free survival, as
well as decreased rates of drug resistant cancer cells. Therefore, the goal of this review is to
promote the application of dual treatment therapy on relapsed ALL cells for improved outcome,
as well as on primary ALL cells for decreased drug resistance.

Key Words: acute lymphoblastic leukemia, pediatric, monoclonal antibody, Blinatumomab,
chemotherapy, dual therapy, relapse, clonal mutation, drug-resistance
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DUAL THERAPY TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
WITH BLINOTUMOMAB AND A STANDARD CHEMOTHERAPY REGIMEN
Introduction
Imagine that you are working to solve an incredibly complex problem, one that takes you
years of hard work, and then finally after multiple heart-wrenching failures you determine a
possible route that shows promising leads to an answer. Then, when you at last feel like a
solution is within reach, a new variable is thrown into the problem that introduces a completely
unforeseen challenge in reaching your end goal. This is oftentimes exactly what the frustrating
battle with cancer can feel like.
There is an abundant selection of promising therapies and treatments for many common
cancers and malignancies, but unfortunately, many of them still result in the cancer returning
with a new set of mutated genes that are prepared to fight even harder than before. Rare cancers
as well face many difficult obstacles to overcome when formulating a treatment plan. It can be a
disheartening battle when treatment initially rids the body of malignant cells, but then new
cancerous cells develop that are specifically made to resist the treatment that was once so
promising.1-3 This is why one of the greatest gifts that can be given to patients with these
devastating afflictions is time. However, with many advances in technology today, there is
potential to outsmart the cancer cells before they have the opportunity to mutate and deceive the
body. With the implementation of dual-therapy treatments in many varieties of cancer, survival
rates have significantly increased.3 There have also been noticeable decreases in rates of
relapse3, which is one of the key indicators measured when analyzing overall survival for cancer
patients. If there was an opportunity for a treatment that not only aided a patient’s immune
system in fighting off cancer cells, but also provided a potential for a lower risk of relapse, all
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measures should be taken, and all costs be funded in order to achieve this goal. The capability of
a treatment to increase the patient’s quality of life and life expectancy should be a primary goal
in cancer research. Presented within this thesis is a proposal to combine a standard
chemotherapy regimen, which has been shown to limit cancer cell growth and expansion, with an
innovative monoclonal antibody named Blinatumomab to directly target the patient’s immune
response cells to initiate the desired apoptotic effect on cancerous acute lymphoblastic leukemia
cells. Blinatumomab is considered an immunotherapeutic agent because of its ability to
empower the patient’s own immune system to defeat the cancer cells. It has shown great
promise in previous studies with acute lymphoblastic leukemia patients, and in combination with
chemotherapy could be a lifechanging treatment for these children.1,2 In order to accurately
determine the potential for a dual therapy treatment to effectively treat relapsed leukemia
patients, as well as to decrease rates of relapse in primary cancer diagnosed patients, several tests
should be completed. The goals of each test are to examine the efficacy of a dual therapy
treatment in comparison to a monotherapy treatment for both primary and secondary leukemia,
as well as to research a potential treatment for a population of cancer patients that do not contain
the receptor that Blinatumomab targets. If the tests give promising results, then the next goal
would be to move on to clinical trials to determine if the treatments are effective and safe for the
human population.
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Background and Significance
Leukemia, a well-known disease affecting the blood cells, is the number one cancer in the
pediatric population, and the second cause of death in children age’s 0-14.3 There are four
classifications of leukemia including Chronic Myeloid, Chronic Lymphoblastic, Acute Myeloid,
and Acute Lymphoblastic. The most prevalent form in children is Acute Lymphoblastic
Leukemia (ALL), which is diagnosed in approximately 3,800 patients each year, comprising
nearly eighty percent of all ALL cases diagnosed annually.4,5 Since the discovery of leukemia in
the 19th century, the methods of treatment for this significant number of patients have improved
considerably, leading to a substantial increase in patient overall survival rates.3
In 1847 the disease was named by Dr. Rudolf Virchow, a German politician who spent a
large part of his time researching cell biology, pathology and anthropology.6 However, the first
published case of the disease was in 1899 when Major Samuel T. Armstrong, a military surgeon,
died of the disease in Manila.6 By 1913 there had been several more case reports of deaths
caused by leukemia, as well as the discovery of the different classifications of the disease. The
first mention of treatment was in December of 1913, when physicians attempted to treat a student
from Cornell University by performing a blood transfusion with his twin brother, which was
unsuccessful.6 Two years later, doctors discovered that radium was successful in treating
patients, but the poison had severe negative effects on the body systems. However, radiation
therapy is still a widely used treatment for the cancer today. By the 1930’s the disease had been
frequently mentioned, but was still left without a cure, other than futile attempts at blood
transfusions. In 1946 the treatment of leukemia with chemicals was first mentioned in The New
York Times after an anonymous reporter shared that chemical medications rejected for the
treatment of malaria, because they destroyed white blood cells, may be beneficial for anti-
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leukemia therapies.6 Today, there is still no defined cure for leukemia, but treatments such as
chemotherapy, stem cell transplants, and new immunotherapies have significantly increased the
survival rate of diagnosed patients.3
The cause of leukemia varies from patient to patient, but like any cancer there are various
factors that can increase the likelihood of developing the disease. Recent studies have shown
that multiple genetic syndromes can predispose a patient to developing ALL, including Down
syndrome, Fanconi anemia, Bloom syndrome, ataxia telangiectasia, and Nijmegen breakdown
syndrome.5 Other predisposing factors include exposure to pesticides, ionizing radiation, or
certain viruses such as Epstein-Barr Virus or Human Immunodeficiency Virus.5 However, in the
majority of diagnoses the disease develops de novo in previously healthy individuals. ALL can
be further divided into two main classifications, namely, B cell ALL and T cell ALL. Seventyfive to eighty-five percent of all pediatric patients with ALL have cancer cells that developed
from the B cell origin, leading to the arrest of an immature B cell progenitor.7 B-ALL typically
develops in utero as a result of a chromosomal translocation, of which there are many
variations.7 This abnormality causes a differentiation arrest in developing B lymphoid cells,
leading to their suspension in a differentiated state before having reached maturity, or in some
cases they are reverted to a pre-differentiation state and then arrested, causing them to rapidly
proliferate as leukemia blasts.8,9 The leukemia blasts will then advance from the bone marrow
into the bloodstream to penetrate the spleen, liver, central nervous system, thymus and lymph
nodes.2 This takeover of the hematopoietic system also has detrimental effects on red blood cells
and platelets by significantly decreasing their counts within the peripheral blood.8 The negative
effects on the hematopoietic system then have further consequences on other body systems such
as the immunological and physiological systems, many times leading to death.8 There are many
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genetic abnormalities leading to the occurrence of acute lymphoblastic leukemia, including the
formation of the Philadelphia chromosome (see Figure 1). This is typically cause by the
chromosomal fusion of the BCR and ABL genes from chromosomes 9 and 22, producing a
significantly shorter chromosome as well as significant health defects.10 This fusion leads to the
activation of downstream kinases within multiple signaling pathways which causes cells to stray
from their normal signal response, thereby causing proliferation and oncogenesis of leukemia,
many times being initiated in the myeloid compartment.11 The myeloid compartment is a part of
the immune system and contains a large mixed group of myeloid-stemmed cells including
neutrophils, eosinophils, dendritic cells, and mast cells.12 The problem with the interaction of the
myeloid compartment with the Philadelphia chromosome is that all of cells contained within this
section can be affected by the Philadelphia mutation, thereby causing a greater distribution
throughout the body.13 The myeloid cells within the myeloid compartment, when influenced by
cancerous cells, play a large role in the metastatic process of cancer development, from
delamination from the primary tumor mass to the invasion of neighboring tissue to eventual
colonization of the site of metastasis.12 However, in many cases the genetic alterations are not
enough to cause the onset of the disease, and therefore a second factor is required. Potential
secondary contributors to leukemia are currently being studied and include environmental,
ethnic, immunologic, infectious, and socioeconomic components.7
Treatment of acute lymphoblastic leukemia has greatly improved over the years with the
advent of multidrug, risk-adapted chemotherapy regimens, as well as recognition of treatment
response characteristics that can identify patients at risk for treatment failure.14 This has led to
cure rates of approximately 90%, an astounding statistic, however for the 10-20% of pediatric
patients who relapse the outlook is dismal and has shown little to no improvement in the last
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twenty years.15 Current treatment for relapsed ALL is surprisingly similar to primarily
diagnosed patients with the exception that treatment is typically dose intensified or given on
alternative schedules.14 Once a patient reaches second complete remission (CR2) they will
usually continue intensive chemotherapy treatment. Furthermore, a hematopoietic stem cell
transplant is also a potential treatment for the secondary cancer. However, these treatment
strategies have not led to significantly improved overall survival (OS) rates, especially with
relapsed cancers with poor prognostic factors such as early bone marrow relapse, thereby leading
to the need for novel treatment therapies.14
Currently the best primary treatment for patients originally diagnosed with ALL is a
regimen of chemotherapy with the goal of reaching induction, followed by consolidation and
then maintenance therapy.14 The best indicator of long-term survival is the quantity of time a
patient survives disease-free.16 Patients that relapse within one year of being declared diseasefree maintain the most dismal prognosis of long-term survival.17 Therefore, it is vital to
implement treatment options that decreased rates of relapse within patients to give them a great
chance at long-term survival.

Primary Treatment Options
With the increasing percentage of annual leukemia diagnoses in the United States, a
standard treatment protocol for the cancer is required. Typically, when a patient is initially
diagnosed with acute lymphoblastic leukemia, they will undergo a three-phase cancer treatment
process as mentioned above. These three steps include induction (or remission induction),
consolidation (or intensification), and then maintenance therapy.18 The goal of the induction
phase is remission, which is defined as when leukemia cells are no longer found in bone marrow
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tissue samples, normal marrow cells return, and the blood counts become normalized.18 This
does not mean, however, that the patient is “cured”, because there may still be remnant cancer
cells undetected within the patient’s body. Typical chemotherapy drugs administered during the
induction phase include Vincristine, Dexamethasone or prednisone, or Doxorubicin.18
Doxorubicin is an anthracycline antibiotic administered intravenously through either a central or
peripheral venous line.19 Furthermore, Doxorubicin is also a vesicant, meaning that it can cause
severe tissue damage if it escapes from the vein.19 Doxorubicin is an antitumor antibiotic,
meaning that it is derived from a natural product and acts during multiple phases of the cellcycle, thereby making it a cell-cycle specific drug.19 Chemotherapy drugs such as Doxorubicin
are not cancer specific and can target any rapidly dividing cell, leading to common side effects
such as hair loss (alopecia), mouth sores, nausea, and diarrhea.19 Dexamethasone is a second
chemotherapeutic drug commonly used for treatment of ALL. It is a glucocorticosteroid that is
distributed in pill form, many times alongside other chemotherapy drugs.20 It is an antiinflammatory frequently used in the short-term treatment of nausea caused by other
chemotherapy drugs, but it has also been found to cause apoptosis, and can therefore aid in the
fight against the cancerous cells.20 Finally, Vincristine is a third drug commonly used in
treatment for ALL among other cancers.21 It is also a vesicant that is given intravenously, and
risks the same side effects as Doxorubicin.21 Furthermore, it belongs to a class of chemotherapy
drugs called plant alkaloids, and is specifically a member of the vinca alkaloids group. Vinca
alkaloids are microtubule agents that inhibit the microtubule structures within a cell, preventing
proper division and replication, and eventually leading to cell death.21 However, chemotherapy
agents can be extremely toxic to healthy tissue as well as cancer cells, and so it would be
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incredibly beneficial to propose treatment options that minimize use of vesicant chemotherapies,
or eliminate them completely.
Incidence of Relapse
While current treatment therapies for acute lymphoblastic leukemia have led to the
astonishing survival of 90% of patients, the prognosis for the 10-20% that face relapse is
oftentimes discouraging.2 Chromosomal abnormalities, genetic mutations, and decreased
responsiveness to chemotherapy are but a few of the differences seen between primarily
diagnosed leukemia and the relapsed cancer.22 A study done by Mullighan et al.22 researched the
genetic basis of relapse by performing DNA copy number analyses on both diagnosis and relapse
samples from acute lymphoblastic leukemia patients. The results showed a majority of patients
had different copy number abnormalities (CNAs) between relapse and diagnosis, specifically
relapse samples lacked some of the CNAs identified at diagnosis, leading to the conclusion that
genetic anomalies that lead to ALL relapse are brought about during therapeutic treatment and
that the signaling pathways affected by these modifications may be promising targets for
intervention.22 Furthermore, a study done by Greaves et al. also showed how therapeutic
treatment may inadvertently cause resistant variations in the cancer cells to evolve while the
original clonal cells are being exterminated.23 Studying matched pair samples from the same
patient has allowed for observation of the biological pathways responsible for the drug resistant
phenotype seen at relapse.24,25 Copy number analyses (CNA) were performed by various
researchers to detect copy number variations (CNVs), which are genomic alterations leading to
an abnormal number of copies of one or more genes, due to either deletions, duplications,
translocations or inversions.26 Previous studies have shown that there are distinct genetic
alterations between diagnosed leukemia cells and relapsed blasts, and comparison of the two
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samples by CNA has also provided the opportunity to study the clonal evolution over time and
map its origin.24 In fact, studies show that the vast majority (approximately 94%) of relapses are
derived from a clone present at diagnosis, while a small minority (close to 6%) occur from a
genetically new leukemia.14 Nearly 34% of these clones derived from the original cancer were
present at diagnosis, while close to 52% evolved from the ancestral clone, as seen in Figure 2.14
Furthermore, the CNA revealed that focal deletions were more common than additions,
specifically deletions of IKZF1, EBF1, BTG1, TBL1XR1, and MSH6.14 IKZF1 is a gene
responsible for encoding the lymphoid TF IKAROS, and deletion of this gene has been defined
as a strong indicator of relapse.27 Other deletions such as NR3C1, BTG1, and TBL1XR1 have
been identified in B-ALL as factors leading to glucocorticosteroid resistance.28 Along with
genetic deletions present in mutations at relapse, there are also multiple signaling pathways that
can develop genomic lesions, leading to resistance to nearly all drug therapies. Studies done that
performed integrated genomic profiling revealed that the activation of the WNT and MAPK
pathways are frequently observed at relapse, and therefore could be a potential target for
treatment.29
Clonal evolution following therapeutic treatment is becoming an increasingly recognized
topic to begin to study the effects of chemotherapy and radiation treatment on cancer cells, not
just as eradicators of the clonal cells rapidly proliferating, but also as amplifiers of clonal
mutations causing resistance to further therapeutic treatments.30,31

Secondary Treatment Options
Immunotherapy is arguably the most promising leukemia treatment currently being
studied.14 The goal of immunotherapy is to aid the patients’ immune system in fighting off
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leukemic clones rather than merely administering exogenous chemicals to destroy the rapidly
dividing cells. Two of the most increasingly popular immunotherapy methods being studied are
CAR-T cells and monoclonal antibodies. Chimeric antigen receptor T cell (CAR-T cell) therapy
works by engineering T lymphocytes from the patients’ blood with synthetic receptors made to
recognize and eliminate specific cancer cells.32 T cells are initially collected from the peripheral
blood by leukapheresis, followed by apheresis. The separated T cells are then transfected with a
viral or non-viral vector containing the CAR genome, and then expanded and purified.32 Finally,
the cells are tested for quality and sterility, which is a process that takes approximately two to
four weeks (see Figure 3) Before the patient is injected with the resulting cells, they must
undergo a lymphodepletion treatment.32 CAR-T cells have been found to be most beneficial in
the treatment of hematological malignancies such as leukemias, lymphomas, and myelomas .
They are also most effective as anti-CD19 receptors, due to the fact that CD19 is a cell marker
characterized with high expression in B-ALL cells.32 A recent study done by Jae et al. analyzed
the use of CAR-T cell therapy on fifty-three patients with relapsed B-ALL.33 Patients received
an infusion of T-cells expressing 19-28z CARs, meaning that the chimeric receptor was
composed of an anti-CD19 antibody binding site as well as intracellular domains from the T-cell
coactivating receptors CD28 and CD3-zeta chain.33 The results showed that a total of 83% of
patients reached complete remission (CR), with an overall survival of 12.9 months.33 The two
most toxic side effects observed with CAR-T cell treatment were cytokine release syndrome
(CRS) and neurotoxicity.33
Blinatumomab is a monoclonal antibody (mAb) that has been reported as the most
promising agent of innovative ALL treatment currently being studied. It is a bispecific T cell
engager (BiTE) that uses one arm of the antibody (Ab) to bind to CD19 on B cell leukemia cells.
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CD19 is one of the most commonly expressed cell surface markers on cancerous lymphoblasts.
The second arm of the Ab binds to healthy CD3+ T cells to facilitate the upregulation of T cell
activation and increased cytotoxicity and apoptosis of the cancer cell.34 The mechanism through
which Blinatumomab works can be seen in Figure 4.35 With the binding of each arm of the
bispecific antibody, it allows for the juxtaposition of CD3+ T-cells to malignant B-cells, which
leads to the production of granzymes and perforins, thereby initiating apoptosis.36
One of the main consequences of treatment with both CAR-T cells and Blinatumomab is
cytokine release syndrome (CRS). Specifically, the increase in IL-6, IL-10, and IFN-γ.37
Clinical manifestations of CRS include high fever, hypotension, hypoxia, and respiratory
distress.38 Furthermore, organ dysfunctions can also occur, including liver transaminitis and
renal insufficiency, as well as other life-threatening complications.38 However, Blinatumomab is
known to have lower rates of CRS in comparison to CAR-T cell therapy.38 Due to the high
increase in expression of IL-6 with CRS, inhibitors specifically for IL-6 have been studied and
shown to dramatically improve effects of CRS.37,38
Blinatumomab has recently been approved by the FDA for the treatment of acute
lymphoblastic leukemia, and has shown increased rates of event-free survival, disease-free
survival, and progression-free survival in comparison to standard chemotherapy treatment
alone.39 However, dual therapy treatments have shown even greater results, especially
monoclonal antibody and chemotherapy combination therapy. Therefore, the dual therapy
treatment of acute lymphoblastic leukemia with Blinatumomab and chemotherapy is a potential
route to increase survival rates in pediatric patients.
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Dual Therapy Treatments
Dual therapy treatment of various cancers is becoming a widely recognized and encouraged
tactic for the battle against cancer. While monotherapy regimens have shown promising results
and are sufficient for the treatment of some patients, there are numerous limitations to response
rates and duration of therapy.40 The goal of combination therapy is to make the target cells more
immunogenic, thereby increasing the effects of the immunotherapy when given with other
treatment regimens. There are several methods by which immunotherapy makes a tumor cell
more immunogenic. The first is by increasing the antigen and MHC Class I expression on the
cancer cell to increase likelihood of T-cells binding to the cell to initiate cell-mediated
apoptosis.40 Another method is by altering the environment around the tumor cell by either
increasing vascular permeability and T-cell secreted molecules that induce cell death, or by
initiating a positive effect on cytotoxic T-cells within the tumor.40 As the result of many
oncologic studies being performed, a key conclusion is that therapeutic resistance occurs much
more commonly in single-agent therapy than with multi-drug therapy.40 Therefore, dual therapy
would be a beneficial treatment for acute lymphoblastic leukemia by making leukemia cells
more immunogenic while at the same time helping the cytotoxic cells of the immune system to
engage these cells more efficiently, leading to an improved response and decreased likelihood of
drug-resistant cells.
Dual therapy regimens have shown very promising results in other cancer studies as well.
For example, Pfreundschuh et al. aimed to explore the impact of CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone)-like chemotherapy regimens partnered with the
monoclonal antibody rituximab for the treatment of large B-cell lymphoma.2 For their study,
824 patients from 18 different countries were randomly assigned to either six cycles of CHOP-
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like chemotherapy and rituximab or six cycles of CHOP-like chemotherapy alone. The main
goal for all of the patients was event-free survival, with secondary goals of overall survival,
progression-free survival, progression under therapy, and frequency of toxic effects.2 After the
median follow-up of 34 months, patients who received the combined chemotherapy-rituximab
therapy had increased three year event-free survival compared with the group who were assigned
only chemotherapy.2 Before beginning treatment, the stage of lymphoma was defined by
physical examination from a physician along with laboratory tests such as hemoglobin, platelets,
total white blood cell count, differential WBC count, bone marrow biopsy, etc. The size of the
tumor mass was assessed by local physicians and a radiologist, and then the patients were
assigned to their trial, either with or without rituximab. The majority of countries participating
in this trial had their patients undergo the CHOP-21 Regimen guidelines, which included 750
mg/m2 cyclophosphamide, 50 mg/m2 doxorubicin, and 2 mg vincristine all given intravenously
on days 1, 22, 443, 64, 85, and 106; and 100 mg of prednisone were given on days 1-5. 22-26,
43-47, 64-68, 85-89, and 106-110.2 Those who were assigned to also receive rituximab followed
this schedule, along with 375 mg/m2 rituximab administered intravenously on days 1, 22, 43, 64,
85, and 106 of the CHOP regimen.2 Patients received follow-up appointments every three
months for the first two years after treatment, and then every six months. Their follow-ups
included the same laboratory tests administered during staging, as well as physical examination
performed by the physician, and a CT of the chest and abdomen.2 The results of which can be
seen in Figure 5.2 Furthermore, the effect of rituximab was also examined specifically in young
patients. In fact, nearly twice as many (41% versus 21%) young good-prognosis patients failed
after chemotherapy treatment alone rather than chemotherapy combined with rituximab.2
Overall, patients who received rituximab and CHOP-like therapy saw a significant increase in
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event-free survival, progression-free survival, and overall survival. Another study done by Sehn
et al. came to the same conclusion that the addition of rituximab to CHOP-like chemotherapy
resulted in significantly improved patient outcomes in the treatment of diffuse large B-cell
lymphoma compared to chemotherapy treatment alone after studying a total of 292 patients.41
In conclusion, dual therapy treatments with monoclonal antibodies and chemotherapy have
shown highly beneficial treatment outcomes when compared to treatment with chemotherapy
alone. Furthermore, treatment of young patients (<20 years) also maintained the finding that the
combined therapy led to increased overall survival, event-free survival, and progression-free
survival. Therefore, it would be worth the cost of adding Blinatumomab into the treatment
regimen for acute lymphoblastic leukemia in the pediatric population.
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Clinical Presentation and Management
Clinical Signs and Symptoms
Being a cancer of the immune system, Acute Lymphoblastic Leukemia presents itself in
many ways, some of them deceptive and misleading. In fact, many symptoms mimic those of
the flu, but while flu symptoms eventually improve, symptoms of ALL will persist and are clear
indicators to make an appointment with a physician.42 Signs and symptoms may include bone
pain, fever, frequent infections, pale skin, shortness of breath, weakness and fatigue, lumps
caused by swollen lymph nodes in the neck, underarms, or groin, and possible bleeding from the
gums.42 Many of these symptoms are a result of the rapid proliferation and accumulation of
undifferentiated lymphoid cells within the bone marrow, peripheral blood, and extramedullary
sites.43 Further symptoms such as anemia, thrombocytopenia, and leukopenia, all of which can
be diagnosed through a physical exam and complete blood count test, can also constitute bone
marrow failure within the disease.43 Accumulation of undifferentiated cells in extramedullary
sites such as the lymph nodes, spleen, and liver can lead to organ enlargement in 20% of
patients.44 Any of these signs and symptoms should be taken as a clear indicator to visit a
physician.

Diagnostic Tests and Tools
Typically if acute lymphoblastic leukemia or any immune system disorder is suspected, a
physician will order various tests to confirm. First is a complete blood count (CBC), which
measures the cell counts of several components and features of blood, including red blood cells
(RBC’s), white blood cells (WBC’s), hemoglobin (Hgb), hematocrit, and platelets.45 Each
component of the blood plays in important role in the overall health of a patient and can give
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insight into underlying medical conditions. Following the CBC, if leukemia is still suspected,
the physician can order a bone marrow test. The bone marrow test consists of a bone marrow
aspiration and/or biopsy. During the aspiration, a needle is inserted most commonly into the
posterior iliac crest to collect a sample of bone marrow fluid.46 If a bone marrow biopsy is also
being performed, then a larger needle will be used to collect a sample of bone marrow tissue
following the aspiration. After the large needle is inserted into the bone, the center of the needle
is removed and the hollow needle moved deeper to capture a tiny sample of bone marrow.47 The
samples will then be sent to a lab where doctors will classify blood cells based on size, shape,
and other molecular features, and hopefully determine the cause of high or low blood cell
counts.48 Diagnosis of acute lymphoblastic leukemia is typically established by the presence of
20% or more lymphoblasts in the bone marrow.43 The samples are originally assessed via
morphology, to search for cancerous cells. If the cells are found to be cancerous, the doctors will
also be able to determine whether the cancer developed from B- or T-cell progenitors, thereby
assisting in the potential treatment plan. The samples may subsequently undergo examination to
analyze potential chromosomal changes.49 Chromosomal analysis can include fluorescence in
situ hybridization (FISH) to produce an image of the specific strands of DNA on each
chromosome.49 Following the bone marrow biopsy, a physician may choose to order an imaging
test such as a computerized tomography (CT) scan, X-ray, or ultrasound to determine if the
cancer has spread to other parts of the body.48 Finally, at the time of diagnosis it is also standard
for the physician to order a lumbar puncture with cerebrospinal fluid (CSF) analysis to evaluate
for central nervous system involvement.43 CNS involvement in acute lymphoblastic leukemia is
a serious clinical problem that requires CNS prophylaxis. Typical chemotherapy treatments and
combination therapies are not sufficient at ridding the CNS of cancer cells, and therefore
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intrathecal chemotherapy and/or cranial irradiation and high-dose systemic chemotherapy are
typically necessary.50 For pediatric patients, however, cranial irradiation is highly
unrecommended. Intrathecal chemotherapy is refers to treatments given through a lumbar
puncture to disperse the drug throughout the spinal cord and CSF.51 It is commonly administered
to children who develop ALL in order to kill any cancer cells that may have spread to the brain
and spinal cord, and prevent any others from rapidly dividing. The treatment is typically given
twice within the first month and then repeated much less frequently.51 All of these tests are
typically administered to properly make an educated and informed diagnosis of leukemia.

Treatment Plan
Once the diagnosis is determined, the physician will then need to begin developing a
treatment plan with the family. While treatment of acute lymphoblastic leukemia has
significantly increased over the years and led to increased survival rates in pediatric patients, the
percentage of patients who relapse and become drug resistant still receive a very dismal
prognosis. Treatment of de novo patients regularly consists of 4 phases: induction,
consolidation, intensification, and maintenance therapy.49 The goal of induction therapy is to rid
the blood and surrounding tissues of as many leukemia cells as possible, preferably >99%.43,52
Following induction, consolidation and intensification therapy are administered to kill any
remaining leukemia cells in order to prevent relapse.49 Remaining cells may include those that
migrate to the brain and spinal cord through the cerebrospinal fluid. In rare cases, leukemia cells
can develop within the bones of the skull, and can then travel to the cerebrospinal fluid thereby
affecting the central nervous system.53 These cancerous cells are not usually affected by
standard chemotherapy treatments and therefore CNS-directed remedies are necessary.
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Eliminating radiation in children prevents the risk of secondary brain tumors and neuroendocrine
failure, as well as other risks associated with the rapidly dividing cells children have. However,
CNS-directed chemotherapy can carry with it the risk of seizures, encephalopathy, and other
neurocognitive toxicities, greatly affecting function and ability of the brain.53 The role and effect
of the CNS in leukemia survival is not fully understood, and future studies in this area could be
extremely beneficial in prevention of relapse ALL and treatment.
Following intensification treatment, maintenance therapy is reached to prevent leukemic
blasts from redeveloping.48 This third phase of treatment typically includes a combination of
methotrexate and 6-mercaptopurine (6-MP).54 This stage usually lasts about two years, and CNS
prophylaxis treatments are typically continued as well during this time.

Resistance to Treatment
The resistance of some cancer cells, causing them to continue growing and dividing after
treatment, leads to a devastating and dismal prognosis. Effectiveness of treatment is determined
by continued tests, such as those mentioned earlier. A complete response shows that all of the
cancer has disappeared and there is no further evidence of disease.55 With a partial response, the
cancer may have shrunk by a percentage but is still evident. If the cancer has neither grown nor
shrunk it is referred to as stable disease, and if there is increased evidence of cancer it is defined
as disease progression.55 If cancer cells that previously appeared to be responding to treatment
begin to grow, it is defined as resistance. There are several reasons the resistance may have
occurred, including the appearance of clonal mutations as previously mentioned. The
chemotherapy, and other factors, can mutate the cells and cause them to become resistant to the
drug. As they multiply, the number of resistant cells can outnumber the cells that are sensitive to
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treatment.55 Another possible mechanism is through gene amplification from a cancer cell that
leads to production of a protein that comprises the effects of the anticancer drug. Cancer cells
may also use a molecule known as p-glycoprotein to pump the drug out of the cell as quickly as
it is coming in.56 These mechanisms all lead to drug resistance, and typically a new drug must be
administered. In the case of resistance in relapsed cancers, the physician may recommend
immunotherapy options or a hematopoietic stem cell transplant over further chemotherapy.
The road to recovery for a cancer patient can be a long battle, especially when resistance
or relapse occurs, and secondary treatments become necessary. The potential to decrease the
need for continued treatment and drugs, such as those used for chemotherapy, through dual
therapy treatments deserves to be investigated. By introducing a combined treatment early on in
the cancer fight, especially one which uses immunotherapy to encourage the patient’s immune
system to do the fighting, it could decrease rates of cancer cell resistance. Immunotherapy
compels cancer cells to become more sensitive to chemotherapy treatment and therefore
increases induced cell death.
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Research Design and Goals
In order to determine the efficacy of dual therapy treatment with Blinatumomab and
chemotherapy, experiments will need to be performed on cancerous cells. The purpose of the
experiments will be to study both relapsed and primary cancer cell lines and to use those results
to eventually proceed to clinical trials. Promising results would show that the dual therapy
treatment leads to more efficient control and minimization of relapsed cancer cell growth, as well
as decreased rates of relapsed cancer cells from primary cell lines in comparison to monotherapy
treatment with either Blinatumomab or the chemotherapy drug vincristine. For these
experiments, B-ALL cell lines should be used rather than murine models because they are better
equipped to study the effects of drug targets on leukemia cells. While a xenogeneic mouse
model is incredibly efficient at engrafting human hematopoietic and leukemia cells, and is
typically the preferred model for in vivo research of human-derived leukemia, it will not be
sufficient for research with Blinatumomab.57,58 Xenogeneic mice are developed without a native
immune system, which is key for their engraftment properties, but means that bispecific T-cell
engagers (BiTE) such as Blinatumomab that are based on the immune system cannot be properly
assessed.58 Therefore, the best model to be used to study the effects of combined therapy on
relapsed leukemia cells would be relapsed leukemia cells from pediatric ALL patients. Benefits
of using patient-derived leukemia cell lines include an unlimited use of cell material, prolonged
storage in liquid nitrogen and recoverability, long-lasting proliferation in culture, and more.59
After undergoing a procedure to separate out the white blood cells from red blood cells in
samples of relapsed B-ALL cell lines, the collection of white blood cells will be tested for
viability. Viable cells are those that are living, and are therefore the only ones used for
experimentation.59 Cell growth will be observed, and then cultures will undergo treatment with
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combined vincristine and Blinatumomab to determine cytotoxicity.59 Cell death is observed
through breakdown of the cell membrane, condensation of nuclear material, and then
fragmentation of the nucleus.60 Previously, cell cytotoxic activity was measured with a
Chromium51 assay, but due to harmful effects of handling the radioactive compound, a new nonradioactive and real-time cytotoxic assay was developed.61,62 Target-cell cytotoxicity is watched
over time by imaging and live fluorescent target cells are measured in 96-well plates.61 These
images can be picked up through a fluorescent reader such as ‘CytationTM 5’.62 By viewing the
relapsed cell lines response to varying pressures, one would be able to sufficiently determine if
dual therapy treatment would be worth projecting into clinical trials. If the group of cultured
cells that are treated with either Blinatumomab or vincristine alone experience a greater
percentage of cell death than those treated with both agents, then the conclusion could be drawn
that there is a reason the agents do not work synergistically when combined. Therefore, further
research would need to be done to examine the reasoning for the null results, and to thereby
determine a renewed method to attack the cancerous cells. However, if the results of the
experiment showed increased apoptosis in cells treated with both vincristine and Blinatumomab,
then the conclusion could be made that the dual therapy treatment does in fact show promise in
fighting relapsed cells, and could potentially move forward into clinical trials.
While the number of patients that recover from primary acute lymphoblastic leukemia
after typical treatment regimens is ever-increasing, the issue of relapse is still one leading to a
dismal prognosis. Therefore, it is vital to determine if Blinatumomab and chemotherapy dual
treatment will be beneficial in decreasing rates of relapse, specifically in the pediatric population.
In order to accomplish this, primary cell lines similar to those that would be used to test the
combined therapy of vincristine and Blinatumomab on relapsed cells would be cultured. Primary
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cell lines would be used because then the potential for this combined therapy to not only increase
survival rates for relapsed patients, but to decrease rates of relapse in this patient population
could be studied. Therefore, these cell lines would also be purified and cultured, and then treated
in groups with either vincristine alone, Blinatumomab alone, or both agents. Cytotoxicity would
be measured again as a means to determine treatment efficacy. There are many factors that have
the potential to be studied within this experiment. Malignant cells that beat the drugs and
continue to divide after treatment is completed would show that the development of resistant
cells may be just as likely as with common treatments currently being practiced and
administered. Furthermore, what if the length of time between treatment and cancer cell
regrowth was significantly increased with this treatment compared to current treatments?
Increasing the time between initial treatment and potential relapse means increasing the time a
child can live cancer free. Or perhaps this treatment leads to an even greater percentage of
cancer cells becoming resistant to chemotherapy agents, and should therefore not be
administered. However, this is highly unlikely considering that the mechanism of Blinatumomab
is to aid the patients’ immune system to target the cancerous cell, thereby making it more
susceptible to the effects of the chemotherapy without highly pressuring it to become resistant.
Therefore, if the results show that the combined treatment of vincristine and Blinatumomab leads
to decreased relapse percentages in the cancer cell lines, increased treatment efficacy, or even an
extended amount of time between primary and secondary cancer development, then with further
studies this combination could be progressed to clinical trials. Clinical trials would be able to
study these processes within the human body, which is a much more complicated experimental
field. There are significantly more factors that can and most likely will affect the treatment of
cancerous leukemia cells. Furthermore, side effects to the patient must also be examined and
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recorded. Cancer cells are incredibly adaptive, especially within the human body, therefore it is
crucial to study the effect treatment has on them in vivo.
One of the issues being faced after treatment with Blinatumomab in acute lymphoblastic
leukemia patients is that patients whose cancer cells develop clones that are CD19- will be
unable to use Blinatumomab, which is known to target CD19 cell surface markers with one of its
antibody arms. Therefore, for the sake of a future potential population of patients, it is crucial to
determine a different cell surface marker on cancerous B cells and to develop a different
monoclonal antibody other than Blinatumomab to target them. CD19- cells are extremely rare,
which is why CD19 is the primary target for both acute lymphoblastic leukemia diagnosis and
now immunotherapy treatment.63 However, with the development of CD19- leukemia cells that
efficiently evade Blinatumomab, it may be necessary to use other known B-cell surface markers
such as CD10, CD22, or CD24 that are strongly expressed on all stages of B-cells except plasma
cells.63
A monoclonal antibody is developed by a process of injecting a mouse with the antigen
of interest, in this case CD3, and allowing its body to create antibodies for this antigen. These
antibodies are then collected and washed. Following the washing stage, the cells are extracted
from the liver and mixed with myeloma cells. Myeloma cells are eternal cells that when merged
with typical cells, will pass on their longevity. This is key in order for more antibodies to be
produced on a larger scale that fight the antigen of interest. Following, the cells will placed on a
HAT medium which will intentionally kill any of the unfused myeloma cells. The cells that
survive will screened by ELISA. ELISA stands for enzyme-linked immuno-absorbent assay, and
is a method used to bind antibodies to soluble antigen lining the wells of a 96-well microtiter
plate. This procedure tests for the binding constant of the antibodies, or in other words, it tests
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their binding affinity to the antigen of choice to determine if they would be efficient and
successful at marking cells for destruction. The monoclonal antibodies that are produced from
this experiment will then be stripped of their disulfide bonds which unite their two halves
together, and then rejoined with each other in a fashion that creates an antibody with two
different heads. With these two heads the antibody is capable of targeting two different cells,
one cancerous and the other normal. This will place them in a juxtaposition for attack from other
components in the body. In order to determine if an antibody accurately binds to the desired
antigen, an enzyme-linked secondary antibody specific for monoclonal immunoglobulins will
then be used to bind to the mAb, which is then visualized by reaction with an appropriate
enzyme that yields a colored product.64 This procedure can be seen in Figure 5. The resulting
antibodies can then be tested further by ELISA to determine binding affinity before placing them
in cell cultures of leukemia cell clones that are CD19-.
Assuming that the previous experiments were successful in increasing relapsed cancer
cell death, as well as decreasing rates of relapsed cancer cells, if this experiment does not show
efficient attacking and destruction of CD19- clones, then it can be concluded that there is a
specific purpose behind targeting the CD19 receptor. This could mean that CD19 is crucial in
the identification of cancer cells by cells of the immune system. Furthermore, if the experiment
shows promising results of the cancer cell lines facing increased cell apoptosis, then it could
prove that the newly generated antibody is capable of treating this specific population of patients.
Furthermore, it would be interesting to continue watching the effects of this antibody on cell
lines to see if new cancer cells develop that do not have the receptor that was targeted by these
new antibodies. Cancer cells are incredibly versatile and adaptable, and are constantly
accommodating themselves in order to survive.
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Conclusion
Acute lymphoblastic leukemia is the number one cancer diagnosed in pediatric patients.
Being derived from leukocytes, leukemia can quickly take over the patients’ immune system,
leading to the devasting side effects of the cancer. Without a properly functioning immune
system a patient is more susceptible to infection, along with other debilitating side effects such as
anemia, fatigue, and heart disease.3 Despite significant increases in survival rates over the years,
outcomes for patients who relapse are much more dismal. Typical treatment protocol for ALL
consists of induction, consolidation, intensification, and maintenance therapy. Chemotherapy
regimens also frequently contain the drugs vincristine and or doxorubicin, which have similar
mechanisms of action in inhibiting the cancer cell cycle. Secondary treatments include
immunotherapy options such as monoclonal antibodies and CAR T-cell therapy, or a
hematopoietic stem cell transplant. Immunotherapy has shown the most significant benefit in
patient outcomes and is therefore becoming the frontrunner in refractory cancer care.
Monoclonal antibodies specifically, like Blinatumomab, have shown some of the greatest
promise in fighting off cancer cells and cell clones that have become drug resistant at relapse.
However, relapse remains to be one of the largest issues in treating cancer patients, and
significantly decreases rates of survival, therefore methods to decrease rates of relapse are
necessary. Current treatments that are being used today have been shown to increase pressure in
the cancer cell environment, leading to the cell developing resistant genes to the therapy that is
being administered. Therefore, a treatment that avoids this pressured environment would be
incredibly beneficial to research and could lead to a significant decrease in cases of relapse.
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Efficacy Over Current Treatments
The use of Blinatumomab in fighting ALL has recently been approved by the FDA for
administration, however the dual therapy treatment of acute lymphoblastic leukemia with
Blinatumomab and chemotherapy such as vincristine is hypothesized to decrease rates of relapse
in the pediatric population. By combining the monoclonal antibody with the chemotherapy, the
immune system will be more equipped to fight off the malignancy. As previously mentioned,
monoclonal antibodies work to enhance the patients’ own immune system at fighting off the
cancer cells. One arm of the antibody targets the CD19 receptor on leukemia cells, while the
other arm targets the CD3 receptor on the functioning white blood cells. Therefore, the white
blood cells of the patient’s body are more adequately prepared to perform their cytotoxic effects
on the cancer cell. The added chemotherapy aids to slow down the cell cycle of the leukemia
cells, increasing the efficacy of the Blinatumomab treatment. This also removes the pressure that
accompanies intensive chemotherapy, thereby leading to promising results and achievements for
leukemia patients in comparison to the results of current treatments. The intensive chemotherapy
that is used in current treatments is incredibly harsh and non-specific, therefore leading to the
debilitating side effects and potential for developed resistance. A patient undergoing
chemotherapy will be constrained by this treatment for 3-5 years.19 Children are typically not
subjected to radiation due to its harmful effects on their rapidly dividing cells, thereby they
require a more intensive or extended chemotherapy treatment regimen. This means more years
they are missing school, missing crucial childhood experiences and relationships, and missing
the opportunity to just “be a kid” because of medical appointments and treatments. This
treatment has the potential to not only impact a child’s medical future and health, but also their
future and the experiences they deserve to have.
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Advantages to Proposed Dual Therapy Treatment
Dual therapy treatment will be successful at both increasing survival rates of relapsed
cancer patients, as well as decreasing rates of relapse in primary cancer patients. With the above
proposed experiments, it can be determined whether the combined treatment of vincristine and
Blinatumomab will be more effective at treating secondary leukemia, preventing relapse from
primary leukemia, and also effectively treating cancers without the CD19 receptor. With the
proposal of a procedure that will not only more effectively treat the cancer, but also decrease the
risk of cancer cells being driven to resistance, the treatment protocol for a patient with acute
lymphoblastic leukemia could be dramatically altered. Rather than undergoing years of
chemotherapy treatment and maintenance, the patient would be able to recruit the help of their
own immune system rather than initially significantly depleting it, which allows for the strongest
response against the cancer cells. Furthermore, by decreasing the risk of relapse for the patient,
it increases their quality of life and life expectancy. The survival rate of patients who relapse is
significantly decreased in comparison to patients diagnosed with the primary cancer.2
Therefore, minimizing relapse rates by preventing resistant cells will increase the overall
survival and overall cancer-free survival rates of a multitude of patients. Along with increasing
their lifespan, patients quality of life will also benefit from this proposed treatment. They will no
longer need to spend hours upon hours going to chemotherapy treatment and living in a
maintenance stage, but will receive time back with the increased efficacy of treatment. All in all,
the benefits of the success of this proposed dual therapy treatment completely lie in the desire for
the patient to receive the best care, and be given the best chance at a long and healthy life.
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Drawbacks and Future Research Design
While there is incredible potential for many advantages to this combination treatment,
there is also potential for problems to occur that will subsequently need to be addressed.
Primarily, if there is no significant change in patient response and cancer cell cytotoxicity with
the combined treatment in comparison to monotherapy treatments, then determining an alternate
route, potentially with an alternate chemotherapy drug, will be necessary. The relationship
between the chemotherapy and Blinatumomab would need to be further examined to determine
Furthermore, there may also be potential for harmful side effects from this treatment as there are
with any new procedure. While this is unexpected, due to the nature of the agents and the
partnership between the monoclonal antibody and the patients cells, side effects are always
present. The majority of the side effects of Blinatumomab are mild and can be easily treated,
and by decreasing the intensity of the chemotherapy many of those side effects should be curbed
as well. However, there are some side effects previously mentioned earlier such as cytokine
release syndrome that will need to be strictly monitored. Many of these will not be recognizable
until continuation into clinical trials, which would occur after success in the proposed
experiments within this paper.
Furthermore, there is also the potential for increased cost of treatment in comparison to
current treatments. By combining chemotherapy with the monoclonal antibody, cost will
initially be remarkably higher. However, the potential for this treatment to decrease hospital
visits, future chemotherapy treatments (including travel fees for the duration of consolidation and
maintenance therapy), essentially outweighs the increased initial cost of the treatment.
Considering that this treatment would also be applied to primary cancer patients in order to
decrease their potential for relapse, it is the hope that families and insurance companies would
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understand that this increased initial cost can provide relief from future costs and concerns that
surface when a patient undergoes relapse.
Overall, there is significant research being done in the field of oncology, which is
necessary due to the ever-changing cancer cell and its numerous methods of expression.
Studying pediatric acute lymphoblastic leukemia could provide hope to many families who are
fighting this seemingly never-ending battle, or for those who are fighting relapse, the seemingly
undefeatable battle. There is still much work to be done, and many questions to be answered, but
the progress that has been made in this field shows that each answer, however small, has purpose
and can be utilized to save a life.
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APPENDIX A

Figure 1. A representation of the formation of the Philadelphia
chromosome from the fusion of the BCR gene and the AML gene. Both
genes reside on the long arm of their respective chromosomes, 9 and 22.7
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APPENDIX B

Figure 2. Various pathways of clonal evolution leading to drug resistant
phenotype of leukemia cells. Note that approximately 94% of relapsed
clones exhibit a direct relationship to the original clone present at
diagnosis.12
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APPENDIX C

Figure 3. The above diagram depicts the process by which CAR-T cells are
engineered and re-administered to the patient. The first step is to remove
healthy leukocytes from the patient by leukapheresis/apheresis, then by
introducing a viral vector into the DNA genome of the cells, they can present
the CAR. Cells are then expanded and purified, then tested for quality and
sterility before being administered to the patient.30
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APPENDIX D

Figure 4. The above image depicts the mechanism through which Blinatumomab binds to CD3
and CD19 receptors to initiate an immune response.33
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APPENDIX E

Figure 5. The above graphs show the comparison between patients who only received
chemotherapy and those who received chemotherapy and the monoclonal antibody rituximab.
Graph A depicts the rate of event-free survival, graph B shows progression-free survival, and
graph C shows overall survival of the 823 patients within the trial.38
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APPENDIX F

Figure 6. The method of monoclonal antibody
production.47
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